ShockWave Medical, Inc. (NASDAQ:SWAV) has earned an average rating of “Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $207.57.
Several brokerages have recently weighed in on SWAV. Morgan Stanley boosted their price objective on shares of ShockWave Medical from $152.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 10th. Zacks Investment Research raised shares of ShockWave Medical from a “hold” rating to a “buy” rating and set a $235.00 target price on the stock in a report on Friday, August 27th. SVB Leerink lifted their target price on shares of ShockWave Medical from $208.00 to $220.00 and gave the company an “outperform” rating in a report on Tuesday, August 10th. Wells Fargo & Company cut shares of ShockWave Medical from an “overweight” rating to an “equal weight” rating and set a $189.00 target price on the stock. in a report on Friday, June 18th. They noted that the move was a valuation call. Finally, Bank of America cut shares of ShockWave Medical from a “buy” rating to a “neutral” rating and lifted their target price for the company from $180.00 to $200.00 in a report on Monday, July 12th.
Shares of ShockWave Medical stock opened at $196.88 on Friday. ShockWave Medical has a 52-week low of $66.09 and a 52-week high of $237.76. The company has a 50 day moving average of $206.94 and a 200 day moving average of $180.28. The company has a quick ratio of 5.65, a current ratio of 6.66 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $6.92 billion, a P/E ratio of -128.68 and a beta of 1.28.
DTC is making small brands big, fast by opening up new wholesale/retail distribution
ShockWave…
